Bristol's Haematology department at University Hospitals Bristol and Weston manages severe aplastic anaemia and refractory chronic ITP patients requiring higher-dose Eltrombopag therapy. Rompag 50mg provides substantial cost savings versus brand Revolade without compromising clinical quality.
Rompag is used at doses up to 150mg daily in aplastic anaemia patients undergoing combination immunosuppressive therapy with anti-thymocyte globulin and cyclosporine. Adding Eltrombopag to this standard regimen produced complete haematologic responses in over 90% of previously untreated severe aplastic anaemia patients in clinical trials — a dramatic improvement over immunosuppression alone.
Bristol haematology pharmacies and specialist clinics can access Rompag with full WHO-GMP documentation for institutional procurement. Visit medshopy.com or WhatsApp +91 82650 41513.
Rompag is used at doses up to 150mg daily in aplastic anaemia patients undergoing combination immunosuppressive therapy with anti-thymocyte globulin and cyclosporine. Adding Eltrombopag to this standard regimen produced complete haematologic responses in over 90% of previously untreated severe aplastic anaemia patients in clinical trials — a dramatic improvement over immunosuppression alone.
Bristol haematology pharmacies and specialist clinics can access Rompag with full WHO-GMP documentation for institutional procurement. Visit medshopy.com or WhatsApp +91 82650 41513.
